We came across a bullish thesis on United Therapeutics Corporation on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on UTHR. United Therapeutics Corporation’s share was trading at $471.99 as of January 15th. UTHR’s trailing and forward P/E were 17.89 and 15.15 respectively according to Yahoo Finance.
Phovoir/Shutterstock.com
United Therapeutics Corporation is a commercial-stage biotechnology company built around treprostinil, a prostacyclin...
